Haverford Trust Co. Has $304,000 Position in Zimmer Biomet Holdings Inc (ZBH)

Haverford Trust Co. Has $304,000 Position in Zimmer Biomet Holdings Inc (ZBH)

A number of other large investors also recently made changes to their positions in ZBH. Johnson Financial Group Inc. increased its position in shares of Zimmer Biomet Holdings by 17.4% in the fourth quarter. Johnson Financial Group Inc. now owns 977 shares of the medical equipment provider’s stock worth $100,000 after buying an additional 145 shares during the period. Independent Advisor Alliance acquired a new position in shares of Zimmer Biomet Holdings during the fourth quarter worth about $103,000. Capital Guardian Trust Co. increased its position in shares of Zimmer Biomet Holdings by 52.1% in the fourth quarter. Capital Guardian Trust Co. now owns 1,229 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 421 shares during the period. Ledyard National Bank increased its position in shares of Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 110 shares during the period. Finally, Webster Bank N. A. increased its position in shares of Zimmer Biomet Holdings by 12.0% in the first quarter. Webster Bank N. A. now owns 1,447 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 155 shares during the period. Institutional investors and hedge funds own 86.62% of the company’s stock.

Haverford Trust Co. increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 13.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,490 shares of the medical equipment provider’s stock after buying an additional 300 shares during the period. Haverford Trust Co.’s holdings in Zimmer Biomet Holdings were worth $304,000 at the end of the most recent reporting period.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) opened at 118.78 on Tuesday. The firm has a 50 day moving average price of $119.79 and a 200 day moving average price of $113.75. Zimmer Biomet Holdings Inc has a 12-month low of $95.63 and a 12-month high of $133.21. The stock has a market cap of $23.95 billion, a PE ratio of 48.62 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.11 by $0.02. The firm had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 16.66% and a net margin of 3.90%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.00 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings Inc will post $8.54 EPS for the current year.

A number of research analysts have issued reports on the company. Goldman Sachs Group Inc assumed coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective for the company. Canaccord Genuity restated a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Oppenheimer Holdings Inc. set a $132.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, April 28th. Needham & Company LLC upped their price objective on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research note on Friday, April 28th. Finally, Wells Fargo & Co downgraded Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings has an average rating of “Buy” and an average price target of $133.82.

In other news, VP Chad F. Phipps sold 6,200 shares of the company’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David C. Dvorak sold 87,331 shares of the company’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $116.47, for a total value of $10,171,441.57. Following the completion of the transaction, the insider now directly owns 381,886 shares of the company’s stock, valued at approximately $44,478,262.42. The disclosure for this sale can be found here. In the last ninety days, insiders sold 94,571 shares of company stock valued at $11,021,849. Corporate insiders own 1.22% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “ZBH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Related posts

Leave a Comment